8-K: Turnstone Biologics Advances Selected TIL Therapy for Solid Tumors, Initial Clinical Data Expected Mid-2024

Turnstone Biologics is pioneering next-generation Selected TIL therapy, with initial clinical data from Phase 1 trials expected in mid-2024, targeting a range of solid tumors including colorectal, head and neck, and breast cancers.

Summary

• Turnstone Biologics is focused on developing next-generation tumor-infiltrating lymphocyte (TIL) therapies, specifically Selected TILs, to treat solid tumors.
• Their approach aims to overcome the limitations of current treatments by selecting and expanding tumor-reactive T cells, which are often present in low numbers in traditional TIL therapies.
• The company's lead asset, TIDAL-01, is being evaluated in multiple Phase 1 studies, with initial clinical data expected in mid-2024.
• Turnstone is targeting underserved patient populations with solid tumors, including colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), uveal melanoma, and breast cancer.
• The company is also developing TIDAL-02, which combines Selected TILs with viral immunotherapy, and is working on next-generation manufacturing and TIL quality enhancements.
• Turnstone is using a proprietary process to select a more potent population of T cells, with the goal of achieving a higher proportion of tumor-reactive T cells in the final product.
• The company is working with external cGMP manufacturers and has a fully operational TIL therapy process at their San Diego facility.
• Turnstone is optimizing the overall manufacturing time towards a target of 4 weeks and plans to develop a fully integrated commercial manufacturing supply chain once clinical success of TIDAL-01 is demonstrated.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Turnstone's technology and clinical trials, with a clear focus on addressing unmet needs in solid tumor treatment. The company has a strong team and is making progress in its clinical development. However, the risks associated with clinical trials and the early stage of development temper the overall sentiment.

Positives

• Turnstone's Selected TIL approach has the potential to overcome the limitations of traditional TIL therapies by focusing on tumor-reactive T cells.
• The company is targeting multiple high-value solid tumor indications with significant unmet needs.
• Initial clinical data from Phase 1 trials is expected in mid-2024, which could provide early validation of their approach.
• Turnstone has a strong executive team with experience in drug development and manufacturing.
• The company is collaborating with prominent scientific and corporate advisors and collaborators.
• The company is optimizing manufacturing processes to reduce time and cost.
• The company is developing a pipeline of TIL therapies, including combinations with viral immunotherapy and next-generation manufacturing techniques.

Negatives

• The company's therapies are still in early stages of development, and there is no guarantee of clinical success.
• The company is targeting difficult-to-treat tumors, which may present challenges in achieving significant clinical responses.
• The company is reliant on external cGMP manufacturers for some of its clinical trials.
• The company is competing with other companies developing TIL therapies, including those with FDA-approved products.

Risks

• The company's forward-looking statements are subject to substantial risks and uncertainties, including the potential for actual results to differ materially from expectations.
• The company's clinical trials may not be successful, and their product candidates may not receive regulatory approval.
• The company may face challenges in manufacturing and scaling up their TIL therapies.
• The company may face competition from other companies developing similar therapies.
• The company's financial performance may be affected by the success or failure of their clinical trials and product development efforts.

Future Outlook

Turnstone anticipates providing an initial clinical update across their trials in mid-2024 and is focused on demonstrating the benefit of TIDAL-01 in solid tumors where objective response and/or durability of bulk TILs has not been established. They also plan to develop a fully integrated commercial manufacturing supply chain once clinical success of TIDAL-01 is demonstrated.

Management Comments

• Turnstone's mission is to profoundly transform the treatment paradigm for patients with a broad range of solid tumors with next-generation TIL therapies.
• The company believes the key to overcoming challenges of CRC and other cold tumors is large numbers of on-target tumor-reactive T cells.
• Turnstone intends to demonstrate the benefit of TIDAL-01 in solid tumors where objective response and/or durability of bulk TILs has not been established.

Industry Context

The announcement comes in the context of increasing interest in TIL therapies for solid tumors, with the recent FDA approval of Amtagvi for advanced melanoma highlighting the potential of this approach. Turnstone is positioning itself as a leader in next-generation TIL therapies, aiming to expand the applicability of TILs to a broader range of solid tumors.

Comparison to Industry Standards

• The first FDA approved TIL therapy, Amtagvi, is a first-generation bulk TIL therapy approved to treat only advanced melanoma, while Turnstone is developing a next-generation Selected TIL therapy designed to address a broader range of solid tumors.
• Academic studies have shown limited success of bulk TILs in epithelial malignancies, while Turnstone's Selected TIL approach has shown early clinical evidence of objective responses in multiple solid tumor types.
• Competitor companies are developing bulk TIL therapies, but Turnstone is differentiating itself by focusing on the selection and expansion of tumor-reactive T cells.
• Turnstone's approach is based on advances from academia, including work done at the National Cancer Institute (NCI) and Moffitt Cancer Center, which have shown early clinical evidence for selected TIL approaches.
• The company is targeting indications such as colorectal cancer, where current treatment options have limited efficacy and there are no approved immunotherapies for MSS-CRC, which comprises 85% of all CRC cases.

Stakeholder Impact

• Shareholders may benefit from the potential success of Turnstone's clinical trials and product development.
• Employees may benefit from the company's growth and success.
• Patients with solid tumors may benefit from the development of new and effective treatment options.
• The company's suppliers and collaborators may benefit from the company's growth and success.

Next Steps

• Turnstone anticipates providing an initial clinical update across their trials in mid-2024.
• The company will continue to enroll patients in their Phase 1 clinical trials.
• Turnstone will continue to optimize their manufacturing processes.
• The company plans to develop a fully integrated commercial manufacturing supply chain once clinical success of TIDAL-01 is demonstrated.

Key Dates

Keywords

TIL therapy, Selected TILs, solid tumors, immunotherapy, colorectal cancer, head and neck cancer, uveal melanoma, breast cancer, TIDAL-01, TIDAL-02, tumor-reactive T cells, clinical trials, manufacturing